Cargando…

Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study

We leveraged genetic variants associated with caffeine metabolism in the two-sample Mendelian randomization framework to investigate the effect of plasma caffeine levels on the risk of Alzheimer’s disease and Parkinson’s disease. Genetic association estimates for the outcomes were obtained from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsson, Susanna C., Woolf, Benjamin, Gill, Dipender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102212/
https://www.ncbi.nlm.nih.gov/pubmed/35565667
http://dx.doi.org/10.3390/nu14091697
_version_ 1784707276662112256
author Larsson, Susanna C.
Woolf, Benjamin
Gill, Dipender
author_facet Larsson, Susanna C.
Woolf, Benjamin
Gill, Dipender
author_sort Larsson, Susanna C.
collection PubMed
description We leveraged genetic variants associated with caffeine metabolism in the two-sample Mendelian randomization framework to investigate the effect of plasma caffeine levels on the risk of Alzheimer’s disease and Parkinson’s disease. Genetic association estimates for the outcomes were obtained from the International Genomics of Alzheimer’s Project, the International Parkinson’s Disease Genomics consortium, the FinnGen consortium, and the UK Biobank. Genetically predicted higher plasma caffeine levels were associated with a non-significant lower risk of Alzheimer’s disease (odds ratio 0.87; 95% confidence interval 0.76, 1.00; p = 0.056). A suggestive association was observed for genetically predicted higher plasma caffeine levels and lower risk of Parkinson’s disease in the FinnGen consortium. but not in the International Parkinson’s Disease Genomics consortium; no overall association was found (odds ratio 0.92; 95% confidence interval 0.77, 1.10; p = 0.347). This study found possible suggestive evidence of a protective role of caffeine in Alzheimer’s disease. The association between caffeine and Parkinson’s disease requires further study.
format Online
Article
Text
id pubmed-9102212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91022122022-05-14 Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study Larsson, Susanna C. Woolf, Benjamin Gill, Dipender Nutrients Communication We leveraged genetic variants associated with caffeine metabolism in the two-sample Mendelian randomization framework to investigate the effect of plasma caffeine levels on the risk of Alzheimer’s disease and Parkinson’s disease. Genetic association estimates for the outcomes were obtained from the International Genomics of Alzheimer’s Project, the International Parkinson’s Disease Genomics consortium, the FinnGen consortium, and the UK Biobank. Genetically predicted higher plasma caffeine levels were associated with a non-significant lower risk of Alzheimer’s disease (odds ratio 0.87; 95% confidence interval 0.76, 1.00; p = 0.056). A suggestive association was observed for genetically predicted higher plasma caffeine levels and lower risk of Parkinson’s disease in the FinnGen consortium. but not in the International Parkinson’s Disease Genomics consortium; no overall association was found (odds ratio 0.92; 95% confidence interval 0.77, 1.10; p = 0.347). This study found possible suggestive evidence of a protective role of caffeine in Alzheimer’s disease. The association between caffeine and Parkinson’s disease requires further study. MDPI 2022-04-19 /pmc/articles/PMC9102212/ /pubmed/35565667 http://dx.doi.org/10.3390/nu14091697 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Larsson, Susanna C.
Woolf, Benjamin
Gill, Dipender
Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
title Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
title_full Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
title_fullStr Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
title_full_unstemmed Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
title_short Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
title_sort plasma caffeine levels and risk of alzheimer’s disease and parkinson’s disease: mendelian randomization study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102212/
https://www.ncbi.nlm.nih.gov/pubmed/35565667
http://dx.doi.org/10.3390/nu14091697
work_keys_str_mv AT larssonsusannac plasmacaffeinelevelsandriskofalzheimersdiseaseandparkinsonsdiseasemendelianrandomizationstudy
AT woolfbenjamin plasmacaffeinelevelsandriskofalzheimersdiseaseandparkinsonsdiseasemendelianrandomizationstudy
AT gilldipender plasmacaffeinelevelsandriskofalzheimersdiseaseandparkinsonsdiseasemendelianrandomizationstudy